FDA Approves PRRT to Treat Neuroendocrine Tumors

  Patients with inoperable or metastasized neuroendocrine tumors (NETs) may now benefit from recently FDA approved peptide receptor radionuclide therapy (PRRT) according to a recent article in MedPage Today. The…

Continue Reading FDA Approves PRRT to Treat Neuroendocrine Tumors